CRDF Insider Trading Activity and SEC Form 4 Filings
CRDF insider trading summary
Over the past 12 months, insiders at Cardiff Oncology, Inc. (CRDF) reported 4 open-market purchases worth $1.1M by 2 insiders and no sales on SEC Form 4. Net insider buying was $1.1M.
Latest CRDF insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 14, 2026 | Gary W Pace | Insider | Buy | $1000K (687,285 @ $1.46) |
| Jul 14, 2026 | Mani Mohindru | Chief Executive Officer | Buy | $50K (34,364 @ $1.46) |
| Jun 18, 2026 | Mani Mohindru | Chief Executive Officer | Buy | $30K (24,703 @ $1.21) |
| Jun 18, 2026 | Gary W Pace | Insider | Buy | $37K (30,000 @ $1.22) |
| Jul 30, 2025 | Gary W Pace | Insider | Buy | $674K (275,000 @ $2.45) |
| Jul 30, 2025 | Gary W Pace | Insider | Buy | $37K (15,000 @ $2.45) |
| Dec 18, 2024 | James E. Levine | Chief Financial Officer | Buy | $12K (2,400 @ $5.00) |
| Dec 17, 2024 | James E. Levine | Chief Financial Officer | Buy | $15K (2,752 @ $5.42) |
| Dec 16, 2024 | James E. Levine | Chief Financial Officer | Buy | $10K (2,564 @ $3.83) |
| Dec 12, 2024 | Renee P Tannenbaum | Insider | Buy | $34K (10,000 @ $3.42) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.